Barr Cleared Of Infringing Three Patents In Allegra Case

Law360, New York (July 1, 2004, 12:00 AM EDT) -- A U.S. district court has cleared Barr Laboratories of infringing three patents at the center of the generic drug maker’s challenge involving Aventis’ Allegra blockbuster allergy drug.

The U.S. District Court for the District of New Jersey granted summary judgment of noninfringement of three patents in Barr’s challenge for Fexofenadine Hydrochloride, the generic name of the allergy treatment.

Five other patents remain pending in the litigation and two additional patents have been asserted by Aventis and AMR Technology, Inc. against Barr's products in a case filed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.